Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.

Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW.

Lancet. 2019 Sep 30. pii: S0140-6736(19)32215-9. doi: 10.1016/S0140-6736(19)32215-9. [Epub ahead of print]

PMID:
31582314
2.

Asthma progression and mortality: the role of inhaled corticosteroids.

O'Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P.

Eur Respir J. 2019 Jul 18;54(1). pii: 1900491. doi: 10.1183/13993003.00491-2019. Print 2019 Jul. Review.

3.

Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations.

Papi A, Petruzzelli S, Vezzoli S, Georges G, Fabbri LM.

Eur Respir J. 2019 Apr 18;53(4). pii: 1900147. doi: 10.1183/13993003.00147-2019. Print 2019 Apr. No abstract available.

PMID:
31000665
4.

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.

Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A.

Int J Chron Obstruct Pulmon Dis. 2019 Feb 28;14:531-546. doi: 10.2147/COPD.S196383. eCollection 2019.

5.

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation.

Singh D, Fabbri LM, Corradi M, Georges G, Guasconi A, Vezzoli S, Petruzzelli S, Papi A.

Eur Respir J. 2019 May 18;53(5). pii: 1900235. doi: 10.1183/13993003.00235-2019. Print 2019 May. No abstract available.

PMID:
30792343
6.

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.

Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 12;13:3971-3981. doi: 10.2147/COPD.S185975. eCollection 2018. Review.

7.

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.

Siddiqui SH, Pavord ID, Barnes NC, Guasconi A, Lettis S, Pascoe S, Petruzzelli S.

Int J Chron Obstruct Pulmon Dis. 2018 Nov 6;13:3669-3676. doi: 10.2147/COPD.S179425. eCollection 2018.

8.

Inhaled triple therapy in chronic obstructive pulmonary disease - Authors' reply.

Papi A, Singh D, Petruzzelli S, Guasconi A, Vestbo J.

Lancet. 2018 Sep 29;392(10153):1113-1114. doi: 10.1016/S0140-6736(18)31778-1. No abstract available.

PMID:
30303077
9.

Inhaled corticosteroid containing combinations and mortality in COPD.

Vestbo J, Fabbri L, Papi A, Petruzzelli S, Scuri M, Guasconi A, Vezzoli S, Singh D.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801230. doi: 10.1183/13993003.01230-2018. Print 2018 Dec. No abstract available.

PMID:
30209195
10.

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.

Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D.

Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9. Erratum in: Lancet. 2018 Feb 26;:.

PMID:
29429593
11.

The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study.

Singh D, Vezzoli S, Petruzzelli S, Papi A.

Int J Chron Obstruct Pulmon Dis. 2017 Nov 3;12:3263-3271. doi: 10.2147/COPD.S141416. eCollection 2017.

12.

Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.

Singh D, Corradi M, Spinola M, Papi A, Usmani OS, Scuri M, Petruzzelli S, Vestbo J.

Int J Chron Obstruct Pulmon Dis. 2017 Oct 6;12:2917-2928. doi: 10.2147/COPD.S146822. eCollection 2017. Review.

13.

High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.

Paggiaro P, Corradi M, Latorre M, Raptis H, Muraro A, Gessner C, Siergiejko Z, Scuri M, Petruzzelli S.

BMC Pulm Med. 2016 Dec 9;16(1):180.

14.

High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.

Corradi M, Spinola M, Petruzzelli S, Kuna P.

Ther Adv Respir Dis. 2016 Oct;10(5):492-502. doi: 10.1177/1753465816654442. Epub 2016 Jun 23. Review.

15.

Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.

Singh D, Corradi M, Spinola M, Petruzzelli S, Papi A.

NPJ Prim Care Respir Med. 2016 Jun 16;26:16030. doi: 10.1038/npjpcrm.2016.30. Review.

16.

The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).

Singh D, Schröder-Babo W, Cohuet G, Muraro A, Bonnet-Gonod F, Petruzzelli S, Hoffmann M, Siergiejko Z; TRIDENT study investigators.

Respir Med. 2016 May;114:84-90. doi: 10.1016/j.rmed.2016.03.018. Epub 2016 Mar 26.

17.

Correction to: Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations.

Grinyó JM, Petruzzelli S.

Expert Rev Clin Immunol. 2015 Apr;11(4):547. doi: 10.1586/1744666X.2015.1024497. No abstract available.

PMID:
25779682
18.

Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations.

Grinyó JM, Petruzzelli S.

Expert Rev Clin Immunol. 2014 Dec;10(12):1567-79. doi: 10.1586/1744666X.2014.983903. Review. Erratum in: Expert Rev Clin Immunol. 2015 Apr;11(4):547.

PMID:
25407098
19.

Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.

Kanniess F, Scuri M, Vezzoli S, Francisco C, Petruzzelli S.

Pulm Pharmacol Ther. 2015 Feb;30:121-7. doi: 10.1016/j.pupt.2014.07.006. Epub 2014 Aug 1.

20.

Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations.

Wedzicha JA, Singh D, Vestbo J, Paggiaro PL, Jones PW, Bonnet-Gonod F, Cohuet G, Corradi M, Vezzoli S, Petruzzelli S, Agusti A; FORWARD Investigators.

Respir Med. 2014 Aug;108(8):1153-62. doi: 10.1016/j.rmed.2014.05.013. Epub 2014 Jun 6. Erratum in: Respir Med. 2015 Mar;109(3):434-5.

21.
22.

Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.

Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, Fabbri LM, Rabe KF.

Lancet Respir Med. 2013 Mar;1(1):23-31. doi: 10.1016/S2213-2600(13)70012-2. Epub 2013 Mar 4.

PMID:
24321801
23.

Relief of methacholine-induced bronchospasm with extrafine beclomethasone dipropionate/formoterol in comparison with salbutamol in asthma.

Singh D, Corradi M, Bindi E, Baronio R, Petruzzelli S, Paggiaro P.

Pulm Pharmacol Ther. 2012 Oct;25(5):392-8. doi: 10.1016/j.pupt.2012.07.004. Epub 2012 Jul 25.

PMID:
22842339
24.

A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations.

Singh D, Kampschulte J, Wedzicha JA, Jones PW, Cohuet G, Corradi M, Higenbottam T, Petruzzelli S, Vestbo J.

Eur Respir J. 2013 Jan;41(1):12-7. doi: 10.1183/09031936.00207611. Epub 2012 May 31.

25.

Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.

Calverley PM, Kuna P, Monsó E, Costantini M, Petruzzelli S, Sergio F, Varoli G, Papi A, Brusasco V.

Respir Med. 2010 Dec;104(12):1858-68. doi: 10.1016/j.rmed.2010.09.008. Epub 2010 Oct 20.

26.

Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.

Behr J, Demedts M, Buhl R, Costabel U, Dekhuijzen RP, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Lankhorst I, Sardina M, Boissard G; IFIGENIA study group.

Respir Res. 2009 Oct 27;10:101. doi: 10.1186/1465-9921-10-101.

27.

Characterization of the bacteriolytic activity of nutritionally variant streptococci.

Lampis G, Desogus A, Petruzzelli S, Laconi S, Ingianni A, Madeddu MA, Pompei R.

Anaerobe. 2007 Oct-Dec;13(5-6):238-43. Epub 2007 Aug 12.

PMID:
17889570
28.

High-dose acetylcysteine in idiopathic pulmonary fibrosis.

Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M; IFIGENIA Study Group.

N Engl J Med. 2005 Nov 24;353(21):2229-42.

29.

Cell division in cocci: localization and properties of the Streptococcus pneumoniae FtsA protein.

Lara B, Rico AI, Petruzzelli S, Santona A, Dumas J, Biton J, Vicente M, Mingorance J, Massidda O.

Mol Microbiol. 2005 Feb;55(3):699-711.

30.

COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma.

Papi A, Casoni G, Caramori G, Guzzinati I, Boschetto P, Ravenna F, Calia N, Petruzzelli S, Corbetta L, Cavallesco G, Forini E, Saetta M, Ciaccia A, Fabbri LM.

Thorax. 2004 Aug;59(8):679-81.

31.

Kit expression in small cell carcinomas of the lung: effects of chemotherapy.

Rossi G, Cavazza A, Marchioni A, Migaldi M, Bavieri M, Facciolongo N, Petruzzelli S, Longo L, Tamberi S, Crinò L.

Mod Pathol. 2003 Oct;16(10):1041-7.

32.

Cigarette smoke extract induces oxidative stress and apoptosis in human lung fibroblasts.

Carnevali S, Petruzzelli S, Longoni B, Vanacore R, Barale R, Cipollini M, Scatena F, Paggiaro P, Celi A, Giuntini C.

Am J Physiol Lung Cell Mol Physiol. 2003 Jun;284(6):L955-63. Epub 2003 Jan 24.

33.

Effects of nicotine replacement therapy on markers of oxidative stress in cigarette smokers enrolled in a smoking cessation program.

Petruzzelli S, Tavanti LM, Pulerà N, Fornai E, Puntoni R, Celi A, Giuntini C.

Nicotine Tob Res. 2000 Nov;2(4):345-50.

PMID:
11197314
34.

A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.

Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, Lopes Pegna A, Petruzzelli S, Bonifazi V, Orlandini C, Franco Conte P.

Cancer. 2000 Oct 15;89(8):1714-9.

PMID:
11042565
35.

Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study.

Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, Lopes Pegna A, Petruzzelli S, Algeri R, Bonifazi V, Fioretto ML, Orlandini C, Conte PF.

Lung Cancer. 2000 Feb;27(2):75-80.

PMID:
10688490
36.

ICAM-1-independent adhesion of neutrophils to phorbol ester-stimulated human airway epithelial cells.

Celi A, Cianchetti S, Petruzzelli S, Carnevali S, Baliva F, Giuntini C.

Am J Physiol. 1999 Sep;277(3):L465-71. doi: 10.1152/ajplung.1999.277.3.L465.

PMID:
10484453
37.

Serum antibodies to benzo(a)pyrene diol epoxide-DNA adducts in the general population: effects of air pollution, tobacco smoking, and family history of lung diseases.

Petruzzelli S, Celi A, Pulerà N, Baliva F, Viegi G, Carrozzi L, Ciacchini G, Bottai M, Di Pede F, Paoletti P, Giuntini C.

Cancer Res. 1998 Sep 15;58(18):4122-6.

38.

A rapid method for screening large numbers of environmental microorganisms for antiviral activity.

Maullu C, Lampis G, Deidda D, Petruzzelli S, Pompei R.

Appl Environ Microbiol. 1998 Mar;64(3):1161-2.

39.

Limitations of ECG in diagnosing pulmonary embolism.

Petruzzelli S, Palla A, Giuntini C.

Chest. 1998 Feb;113(2):559. No abstract available.

PMID:
9498990
40.

Plasma 3-nitrotyrosine in cigarette smokers.

Petruzzelli S, Puntoni R, Mimotti P, Pulerà N, Baliva F, Fornai E, Giuntini C.

Am J Respir Crit Care Med. 1997 Dec;156(6):1902-7.

PMID:
9412573
42.

Genotypic differentiation of Gardnerella vaginalis by amplified ribosomal DNA restriction analysis (ARDRA).

Ingianni A, Petruzzelli S, Morandotti G, Pompei R.

FEMS Immunol Med Microbiol. 1997 May;18(1):61-6.

43.

Presence and persistence of serum anti-benzo[a]pyrene diolepoxide-DNA adduct antibodies in smokers: effects of smoking reduction and cessation.

Pulerà N, Petruzzelli S, Celi A, Puntoni R, Fornai E, Säwe U, Paoletti P, Giuntini C.

Int J Cancer. 1997 Jan 17;70(2):145-9.

44.

Detection of N7-methyldeoxyguanosine adducts in human pulmonary alveolar cells.

Petruzzelli S, Tavanti LM, Celi A, Giuntini C.

Am J Respir Cell Mol Biol. 1996 Aug;15(2):216-23.

PMID:
8703477
45.

Karalicin, a new biologically active compound from Pseudomonas fluorescens/putida. II. Biological properties.

Lampis G, Deidda D, Maullu C, Petruzzelli S, Pompei R, Monache FD, Satta G.

J Antibiot (Tokyo). 1996 Mar;49(3):263-6.

46.

Karalicin, a new biologically active compound from Pseudomonas fluorescens/putida. I. Production, isolation, physico-chemical properties and structure elucidation.

Lampis G, Deidda D, Maullu C, Petruzzelli S, Pompei R, Monache FD, Satta G.

J Antibiot (Tokyo). 1996 Mar;49(3):260-2.

47.

A way to select on clinical grounds patients with high risk for pulmonary embolism: a retrospective analysis in a nested case-control study.

Donnamaria V, Palla A, Petruzzelli S, Manganelli D, Baldi S, Giuntini C.

Respiration. 1995;62(4):201-4.

PMID:
8578015
48.

The role of suspicion in the diagnosis of pulmonary embolism.

Palla A, Petruzzelli S, Donnamaria V, Giuntini C.

Chest. 1995 Jan;107(1 Suppl):21S-24S. Review.

PMID:
7813324
49.

Host factors in lung carcinogenesis.

Petruzzelli S, Giuntini C.

Monaldi Arch Chest Dis. 1994 Jun;49(3):235-8. Review.

PMID:
8087122
50.

Antimicrobial activity of 5-substituted-3-amino-1,2,4-triazoles.

Serra C, Petruzzelli S, Seu GF, Lampis G, Pompei R.

Pharmacol Res. 1994 Jan-Feb;29(1):59-64.

PMID:
8202443

Supplemental Content

Loading ...
Support Center